Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Next Previous
Trial Profile

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 30 May 2025 According to the Telix Japan media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from today, May 30, through June 3, 2025.
  • 03 Mar 2025 According to the Telix Japan media release, Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX, will discuss the details of STARLITE studies of TLX250, in an investors webinar to be held on Tues Mar 11, 5.30pm
  • 13 Feb 2025 According to the Telix Japan media release, data from this study will be presented in a Poster session on February 15, 2025, at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) to be held in San Francisco, CA (US) from 13 - 15 February 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top